AI Article Synopsis
- Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive form of non-small cell lung cancer that typically progresses quickly and often resists standard chemotherapy, leading to a poor prognosis.
- A case report highlights the successful use of selpercatinib, a kinase inhibitor, as a first-line treatment in a patient with advanced pulmonary LCNEC that contains a rare fusion gene.
- The findings emphasize the critical need for early genetic testing in patients with pulmonary LCNEC to allow for more effective targeted therapies.
Article Abstract
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its aggressive behavior. This includes rapid progression, widespread metastases, and resistance to conventional chemotherapy, all of which contribute to a dismal prognosis. Consequently, managing pulmonary LCNEC remains a significant challenge. In this case report, we describe the successful use of selpercatinib (rearranged during transfection) kinase inhibitor, as a first-line treatment in a patient with advanced pulmonary LCNEC harboring a fusion gene. Although fusion genes are exceedingly rare in pulmonary LCNEC, this case underscores the importance of early genetic testing in patients with pulmonary LCNEC to tailor targeted therapies effectively.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440289 | PMC |
| http://dx.doi.org/10.1016/j.rmcr.2024.102116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!